INT11235

Context Info Confidence 0.69 First Reported 1983 Last Reported 2008 Negated 0 Speculated 2 Reported most in Abstract Documents 27 Total Number 29 Disease Relevance 15.32 Pain Relevance 2.57

extracellular space (IFNA2) extracellular region (IFNA2) cell-cell signaling (IFNA2)

Anatomy Link Frequency shields 2 endometrium 1 sublingual 1 joints 1 leukocyte 1 IFNA2 (Homo sapiens)

Pain Link Frequency Relevance Heat psoriasis 3 99.84 tolerance 3 99.70 Pain 37 99.58 narcan 7 99.56 depression 8 99.26 antagonist 1 99.26 opiate 2 99.04 Fibrositis 8 98.30 antidepressant 2 98.00 headache 11 95.88

Disease Link Frequency Relevance Heat Disease 23 99.98 Skin Cancer 9 99.98 Lung Cancer 2 99.98 Myelofibrosis 1 99.96 Pressure And Volume Under Development 5 99.84 Psoriasis 3 99.84 Hepatitis C Virus Infection 19 99.76 Pain 38 99.58 Aseptic Necrosis Of Bone 2 99.58 Multiple Myeloma 4 99.40

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Combination therapy of M2-protocol and interferon-alpha as remission induction in refractory multiple myeloma.

Positive_regulation (induction) of interferon-alpha associated with multiple myeloma

1) Confidence 0.69 Published 1991 Journal Haematologia (Budap) Section Title Doc Link 1813363 Disease Relevance 0.38 Pain Relevance 0.06

Imiquimod [1-(2-methylpropyl)-1H-imidazo[4,5c]quinolin-4-amine] is a compound of low molecular weight that, when administered p.o., induces interferon-alpha in several animal species and inhibits tumor growth in mice.

Positive_regulation (induces) of interferon-alpha associated with cancer

2) Confidence 0.57 Published 1993 Journal Cancer Res. Section Abstract Doc Link 8221654 Disease Relevance 0.35 Pain Relevance 0

Imiquimod induced interferon-alpha in serum in 10 of 19 doses of 200-300 mg.

Positive_regulation (induced) of interferon-alpha

3) Confidence 0.57 Published 1993 Journal Cancer Res. Section Abstract Doc Link 8221654 Disease Relevance 0.35 Pain Relevance 0

Fourteen patients with epithelial ovarian cancer were treated with intraperitoneal (i.p.) administration of alpha-recombinant interferon (rIFN-alpha 2) after documentation of persistent disease at second-look laparotomy and combination chemotherapy.

Positive_regulation (administration) of alpha-recombinant interferon associated with ovarian cancer and disease

4) Confidence 0.49 Published 1985 Journal Cancer Treat. Rev. Section Abstract Doc Link 3833327 Disease Relevance 0.66 Pain Relevance 0

Fourteen patients with epithelial ovarian cancer were treated with intraperitoneal (i.p.) administration of alpha-recombinant interferon (rIFN-alpha 2) after documentation of persistent disease at second-look laparotomy and combination chemotherapy.

Positive_regulation (administration) of rIFN-alpha 2 associated with ovarian cancer and disease

5) Confidence 0.49 Published 1985 Journal Cancer Treat. Rev. Section Abstract Doc Link 3833327 Disease Relevance 0.72 Pain Relevance 0.05

After baseline blood sample collection, the FMS patients were randomized to one of four parallel treatment groups (n = 28/group) to receive sublingual IFN-alpha (15 IU, 50 IU, 150 IU), or placebo every morning for 6 weeks.

Positive_regulation (receive) of IFN-alpha in sublingual associated with fibrositis

6) Confidence 0.49 Published 1999 Journal J. Interferon Cytokine Res. Section Abstract Doc Link 10476945 Disease Relevance 0.49 Pain Relevance 0.33

One patient after 4 weeks of treatment reported increasingly troublesome small joints pain and swelling, which forced leuHuIFN alpha (ldou) discontinuation after 19 weeks.

Positive_regulation (forced) of leuHuIFN alpha in joints associated with pain and pressure and volume under development

7) Confidence 0.49 Published 1993 Journal Arch. Immunol. Ther. Exp. (Warsz.) Section Abstract Doc Link 8129569 Disease Relevance 0.85 Pain Relevance 0.13

METHODS: Fifty patients with chronic hepatitis C who had never received alpha-interferon were randomly assigned to receive 3-8 MU of alpha2b-interferon, three times weekly for 6 months, alone or in association with ketoprofen at a dose of 200 mg/day five times weekly.

Positive_regulation (received) of alpha-interferon

8) Confidence 0.48 Published 1999 Journal Aliment. Pharmacol. Ther. Section Body Doc Link 10540048 Disease Relevance 0.09 Pain Relevance 0

AIM: : To test the hypothesis that ketoprofen may increase the rate of response to alpha-interferon of chronic hepatitis C patients.

Spec (may) Positive_regulation (increase) of alpha-interferon

9) Confidence 0.48 Published 1999 Journal Aliment. Pharmacol. Ther. Section Body Doc Link 10540048 Disease Relevance 0.09 Pain Relevance 0

We have previously shown that the risk of major depression in patients with malignant melanoma undergoing interferon-alpha (IFN-alpha) therapy can be reduced by pretreatment with the antidepressant, paroxetine.

Positive_regulation (undergoing) of interferon-alpha associated with antidepressant, depression and skin cancer

10) Confidence 0.46 Published 2002 Journal Neuropsychopharmacology Section Abstract Doc Link 11927189 Disease Relevance 0.40 Pain Relevance 0.16

We have previously shown that the risk of major depression in patients with malignant melanoma undergoing interferon-alpha (IFN-alpha) therapy can be reduced by pretreatment with the antidepressant, paroxetine.

Positive_regulation (undergoing) of IFN-alpha associated with antidepressant, depression and skin cancer

11) Confidence 0.46 Published 2002 Journal Neuropsychopharmacology Section Abstract Doc Link 11927189 Disease Relevance 0.40 Pain Relevance 0.16

Five patients received only rIL-2 and four were treated with rIL-2 plus subcutaneous injections of IFN-alpha.

Positive_regulation (injections) of IFN-alpha

12) Confidence 0.44 Published 1992 Journal J. Neurooncol. Section Abstract Doc Link 1541981 Disease Relevance 0.25 Pain Relevance 0.05

Adverse events causing interruption of therapy were seizures, aseptic necrosis, and myelofibrosis. alpha-IFN stabilizes the chronic phase of Ph+ CML in some children, is adequately tolerated when administered at a dose of 2.5 to 5 x 10(6) U/m2/d intramuscularly, and results in a significant decrease in the proportion of Ph+ metaphases in some patients. alpha-IFN in combination with an effective cytoreductive agent or agents appears worthy of further clinical testing in this disease.

Positive_regulation (stabilizes) of alpha-IFN associated with aseptic necrosis of bone, myeloid leukemia, convulsion, disease and myelofibrosis

13) Confidence 0.43 Published 1991 Journal Cancer Section Abstract Doc Link 1833044 Disease Relevance 1.40 Pain Relevance 0.19

MATERIALS AND METHODS: A total of 117 consecutive patients with a mean age of 55.1 years who had Peyronie's disease were enrolled in a single-blind, multicenter, placebo controlled, parallel study to determine the efficacy and safety of intralesional interferon alpha-2b therapy (Schering, Kenilworth, New Jersey), including 62 who received placebo and 55 who received interferon alpha-2b.

Positive_regulation (received) of interferon alpha-2b

14) Confidence 0.38 Published 2006 Journal J. Urol. Section Body Doc Link 16753449 Disease Relevance 0.09 Pain Relevance 0

The current report uses interferon alpha-2b (IFN-alpha) as a model antitumor agent, since it is commonly used in the treatment of malignant melanoma and metastatic renal cell carcinoma.

Positive_regulation (uses) of alpha-2b associated with renal cancer and skin cancer

15) Confidence 0.26 Published 2005 Journal Biomed Microdevices Section Abstract Doc Link 15834523 Disease Relevance 0.76 Pain Relevance 0.08

Eight patients with advanced, previously treated non-small cell lung cancer inhaled natural leukocyte interferon-alpha (IFN-alpha) from a dosimeter-equipped jet nebulizer.

Positive_regulation (inhaled) of interferon-alpha in leukocyte associated with lung cancer

16) Confidence 0.26 Published 1989 Journal J. Interferon Res. Section Abstract Doc Link 2546997 Disease Relevance 0.31 Pain Relevance 0.06

A single rising dose tolerance trial of rDNA interferon-alpha 2 (IFN-alpha 2) was conducted in eight patients with the diagnoses of non-Hodgkin's lymphoma (NHL), multiple myeloma, and chronic lymphocytic leukemia (CLL).

Positive_regulation (conducted) of IFN-alpha associated with chronic lymphoid leukemia, lymphatic system cancer, tolerance and multiple myeloma

17) Confidence 0.20 Published 1983 Journal J Biol Response Mod Section Abstract Doc Link 6607323 Disease Relevance 1.18 Pain Relevance 0.11

Peginterferon-alpha-2a (40KD) is produced by the covalent attachment of recombinant interferon-alpha-2a to a branched mobile 40KD polyethylene glycol moiety, which shields the interferon-alpha-2a molecule from enzymatic degradation, reduces systemic clearance and enables once-weekly administration.

Positive_regulation (attachment) of interferon-alpha-2a in shields

18) Confidence 0.19 Published 2002 Journal BioDrugs Section Abstract Doc Link 12102649 Disease Relevance 0.21 Pain Relevance 0

Peginterferon-alpha-2a (40 kD) is produced by the covalent attachment of recombinant interferon-alpha-2a to a branched mobile 40 kD polyethylene glycol moiety, which shields the interferon-alpha-2a molecule from enzymatic degradation, reduces systemic clearance and enables once-weekly administration.

Positive_regulation (attachment) of interferon-alpha-2a in shields

19) Confidence 0.19 Published 2001 Journal Drugs Section Abstract Doc Link 11772139 Disease Relevance 0.21 Pain Relevance 0

A single rising dose tolerance trial of rDNA interferon-alpha 2 (IFN-alpha 2) was conducted in eight patients with the diagnoses of non-Hodgkin's lymphoma (NHL), multiple myeloma, and chronic lymphocytic leukemia (CLL).

Positive_regulation (conducted) of interferon-alpha 2 associated with chronic lymphoid leukemia, lymphatic system cancer, tolerance and multiple myeloma

20) Confidence 0.18 Published 1983 Journal J Biol Response Mod Section Abstract Doc Link 6607323 Disease Relevance 1.18 Pain Relevance 0.11

General Comments

This test has worked.